C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/13 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) C07K 16/18 (2006.01) C07K 16/46 (2006.01) C12N 5/10 (2006.01) C12N 15/85 (2006.01) C12P 21/08 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2105618
Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.
Hanai Nobuo
Hasegawa Mamoru
Koike Masamichi
Kuwana Yoshihisa
Nakamura Kazuyasu
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Kyowa Hakko Kirin Co. Ltd.
Kyowa Hakko Kogyo Co. Ltd.
LandOfFree
Humanized antibodies to ganglioside gm2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized antibodies to ganglioside gm2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized antibodies to ganglioside gm2 will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1750285